Ifinatamab Deruxtecan Receives FDA Breakthrough Therapy Designation in SCLC

1 month ago 38

FDA designates ifinatamab deruxtecan as a breakthrough therapy for extensive-stage small cell lung cancer, promising improved treatment options for patients.

1. Homepage
2. Lung Cancer
3. Ifinatamab Deruxtecan Receives FDA Breakthrough Therapy Designation in SCLC